Chenodeoxycholic acid increases the induction of CYP1A1 in HepG2 and H4IIE cells

Ibrahim,Zein Shaban

doi:10.3892/etm.2015.2719

Chenodeoxycholic acid increases the induction of CYP1A1 in HepG2 and H4IIE cells

Authors:
- Zein Shaban Ibrahim
View Affiliations

Affiliations: Department of Physiology, Faculty of Medicine, Taif University, Taif 21974, Saudi Arabia
Published online on: September 1, 2015 https://doi.org/10.3892/etm.2015.2719
Pages: 1976-1982

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bile acids are considered to promote carcinogenesis. Cytochrome P450 1A1 (CYP1A1) plays a critical role in the biotransformation of drugs and procarcinogens. This study aimed to investigate the ability of bile acids to modulate CYP1A1 expression. Treatment of HepG2 cells with chenodeoxycholic acid (CDCA) and Sudan III (S.III) upregulated CYP1A1 transcriptional activity in HepG2 cells and CYP1A1 mRNA expression in H4IIE cells. Pretreatment of the HepG2 and H4IIE cells with CDCA upregulated the S.III‑induced CYP1A transcriptional activity and mRNA expression. The CDCA‑induced enhancement of CYP1A1 was not abolished by the p38 inhibitor SB203580. However, exposure of the cells to the mitogen‑activated protein kinase kinase (MEK)1/2 inhibitor PD98059 suppressed the CDCA‑induced enhancement of CYP1A1. These results show the ability of CDCA to upregulate CYP1A1 transcription and expression, which may explain the hepatocarcinogenesis‑inducing effect of cholestasis. The CDCA‑induced upregulation of CYP1A1 most probably proceeded through MEK1/2 activation, indicating that this may be a therapeutic target to prevent the cancer‑promoting effects of excessive amounts of bile acids.

View Figures

View References

1	Kuwahara A, Saito T and Kobayashi M: Bile acids promote carcinogenesis in the remnant stomach of rats. J Cancer Res Clin Oncol. 115:423–428. 1989. View Article : Google Scholar : PubMed/NCBI
2	Ross RK, Hartnett NM, Bernstein L and Henderson BE: Epidemiology of adenocarcinomas of the small intestine: Is bile a small bowel carcinogen? Br J Cancer. 63:143–145. 1991. View Article : Google Scholar : PubMed/NCBI
3	Reveille RM, Van Stiegmann G and Everson GT: Increased secondary bile acids in a choledochal cyst. Possible role in biliary metaplasia and carcinoma. Gastroenterology. 99:525–527. 1990.PubMed/NCBI
4	Bayerdörffer E, Mannes GA, Ochsenkühn T, Dirschedl P, Wiebecke B and Paumgartner G: Unconjugated secondary bile acids in the serum of patients with colorectal adenomas. Gut. 36:268–273. 1995. View Article : Google Scholar : PubMed/NCBI
5	Martinez JD, Stratagoules ED, LaRue JM, Powell AA, Gause PR, Craven MT, Payne CM, Powell MB, Gerner EW and Earnest DL: Different bile acids exhibit distinct biological effects: The tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer. 31:111–118. 1998. View Article : Google Scholar : PubMed/NCBI
6	Morvay K, Szentléleki K, Török G, Pintér A, Börzsönyi M and Nawroth R: Effect of change of fecal bile acid excretion achieved by operative procedures on 1,2-dimethylhydrazine-induced colon cancer in rats. Dis Colon Rectum. 32:860–863. 1989. View Article : Google Scholar : PubMed/NCBI
7	Qiao D, Gaitonde SV, Qi W and Martinez JD: Deoxycholic acid suppresses p53 by stimulating proteasome-mediated p53 protein degradation. Carcinogenesis. 22:957–964. 2001. View Article : Google Scholar : PubMed/NCBI
8	Trauner M, Meier PJ and Boyer JL: Molecular pathogenesis of cholestasis. N Engl J Med. 339:1217–1227. 1998. View Article : Google Scholar : PubMed/NCBI
9	Sokol RJ, McKim JM Jr, Goff MC Jr, Ruyle SZ, Devereaux MW, Han D, Packer L and Everson G: Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. Gastroenterology. 114:164–174. 1998. View Article : Google Scholar : PubMed/NCBI
10	Dueland S, Reichen J, Everson GT and Davis RA: Regulation of cholesterol and bile acid homoeostasis in bile-obstructed rats. Biochem J. 280:373–377. 1991. View Article : Google Scholar : PubMed/NCBI
11	Choi J and Ou JH: Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol. 290:G847–G851. 2006. View Article : Google Scholar : PubMed/NCBI
12	Dröge W: Oxidative stress and aging. Adv Exp Med Biol. 543:191–200. 2003. View Article : Google Scholar : PubMed/NCBI
13	Chang GWM and Kam PCA: The physiological and pharmacological roles of cytochrome P450 isoenzymes. Anaesthesia. 54:42–50. 1999. View Article : Google Scholar : PubMed/NCBI
14	Renton KW: Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther. 92:147–163. 2001. View Article : Google Scholar : PubMed/NCBI
15	Lu AY: The 1996 Bernard B. Brodie lecture: A journey in cytochrome P450 and drug metabolism research. Drug Metab Dispos. 26:1168–1173. 1998.PubMed/NCBI
16	Conney AH: Induction of drug-metabolizing enzymes: A path to the discovery of multiple cytochromes P450. Annu Rev Pharmacol Toxicol. 43:1–30. 2003. View Article : Google Scholar : PubMed/NCBI
17	Coon MJ: Cytochrome P450: Nature's most versatile biological catalyst. Annu Rev Pharmacol Toxicol. 45:1–25. 2005. View Article : Google Scholar : PubMed/NCBI
18	Kim D and Guengerich FP: Cytochrome P450 activation of arylamines and heterocyclic amines. Annu Rev Pharmacol Toxicol. 45:27–49. 2005. View Article : Google Scholar : PubMed/NCBI
19	Ma Q and Lu AY: CYP1A induction and human risk assessment: An evolving tale of in vitro and in vivo studies. Drug Metab Dispos. 35:1009–1016. 2007. View Article : Google Scholar : PubMed/NCBI
20	Proctor RN: Tobacco and the global lung cancer epidemic. Nat Rev Cancer. 1:82–86. 2001. View Article : Google Scholar : PubMed/NCBI
21	Whitlock JP Jr, Chichester CH, Bedgood RM, Okino ST, Ko HP, Ma Q, Dong L, Li H and Clarke-Katzenberg R: Induction of drug-metabolizing enzymes by dioxin. Drug Metab Rev. 4:1107–1127. 1997. View Article : Google Scholar
22	Gillner M, Bergman J, Cambillau C and Gustafsson JA: Interactions of rutaecarpine alkaloids with specific binding sites for 2,3,7,8-tetrachlorodibenzo-p-dioxin in rat liver. Carcinogenesis. 10:651–654. 1989. View Article : Google Scholar : PubMed/NCBI
23	Gillner M, Bergman J, Cambillau C and Alexandersson M: Fernström B and Gustafsson JA: Interactions of indolo[3,2-b]carbazoles and related polycyclic aromatic hydrocarbons with specific binding sites for 2,3,7,8-tetrachlorodibenzo-p-dioxin in rat liver. Mol Pharmacol. 44:336–345. 1993.PubMed/NCBI
24	Ciolino HP, Daschner PJ, Wang TT and Yeh GC: Effect of curcumin on the aryl hydrocarbon receptor and cytochrome P450 1A1 in MCF-7 human breast carcinoma cells. Biochem Pharmacol. 56:197–206. 1998. View Article : Google Scholar : PubMed/NCBI
25	Gradelet S, Leclerc J, Siess MH and Astorg PO: β-Apo-8-carotenal, but not β-carotene, is a strong inducer of liver cytochromes P4501A1 and 1A2 in rat. Xenobiotica. 26:909–919. 1996. View Article : Google Scholar : PubMed/NCBI
26	Perdew GH and Babbs CF: Production of Ah receptor ligands in rat fecal suspensions containing tryptophan or indole-3-carbinol. Nutr Cancer. 16:209–218. 1991. View Article : Google Scholar : PubMed/NCBI
27	Ciolino HP, Daschner PJ and Yeh GC: Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. Biochem J. 340:715–722. 1999. View Article : Google Scholar : PubMed/NCBI
28	Canivenc-Lavier MC, Vernevaut MF, Totis M, Siess MH, Magdalou J and Suschetet M: Comparative effects of flavonoids and model inducers on drug-metabolizing enzymes in rat liver. Toxicology. 114:19–27. 1996. View Article : Google Scholar : PubMed/NCBI
29	Whitlock JP Jr: Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol. 39:103–125. 1999. View Article : Google Scholar : PubMed/NCBI
30	Kapitulnik J and Gonzalez FJ: Marked endogenous activation of the CYP1A1 and CYP1A2 genes in the congenitally jaundiced Gunn rat. Mol Pharmacol. 43:722–725. 1993.PubMed/NCBI
31	Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol. 2:533–543. 2001. View Article : Google Scholar : PubMed/NCBI
32	Zollner G, Marschall HU, Wagner M and Trauner M: Role of nuclear receptors in the adaptive response to bile acids and cholestasis: Pathogenetic and therapeutic considerations. Mol Pharm. 3:231–251. 2006. View Article : Google Scholar : PubMed/NCBI
33	Barone M, Maiorano E, Ladisa R, Cuomo R, Pece A, Berloco P, Caruso ML, Valentini AM, Iolascon A, Francavilla A, et al: Influence of ursodeoxycholate-enriched diet on liver tumor growth in HBV transgenic mice. Hepatology. 37:880–886. 2003. View Article : Google Scholar : PubMed/NCBI
34	Zhang CL, Zeng T, Zhao XL and Xie KQ: Garlic oil attenuated nitrosodiethylamine-induced hepatocarcinogenesis by modulating the metabolic activation and detoxification enzymes. Int J Biol Sci. 9:237–245. 2013. View Article : Google Scholar : PubMed/NCBI
35	Ohno M, Ikenaka Y and Ishizuka M: Sudan III dye strongly induces CYP1A1 mRNA expression in HepG2 cells. J Biochem Mol Toxicol. 26:16–22. 2012. View Article : Google Scholar : PubMed/NCBI
36	Amara IE, Anwar-Mohamed A and El-Kadi AO: Mercury modulates the CYP1A1 at transcriptional and posttranslational levels in human hepatoma HepG2 cells. Toxicol Lett. 199:225–233. 2010. View Article : Google Scholar : PubMed/NCBI
37	Qin P: Tang X, Elloso MM and Harnish DC: Bile acids induce adhesion molecule expression in endothelial cells through activation of reactive oxygen species, NF-kappaB, and p38. Am J Physiol Heart Circ Physiol. 291:741–747. 2006. View Article : Google Scholar
38	Shibazaki M, Takeuchi T, Ahmed S and Kikuchi H: Suppression by p38 MAP kinase inhibitors (pyridinyl imidazole compounds) of Ah receptor target gene activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin and the possible mechanism. J Biol Chem. 279:3869–3876. 2004. View Article : Google Scholar : PubMed/NCBI
39	Korashy HM, Anwar-Mohamed A, Soshilov AA, Denison MS and El-Kadi AO: The p38 MAPK inhibitor SB203580 induces cytochrome P450 1A1 gene expression in murine and human hepatoma cell lines through ligand-dependent aryl hydrocarbon receptor activation. Chem Res Toxicol. 24:1540–1548. 2011. View Article : Google Scholar : PubMed/NCBI
40	Allen K, Kim ND, Moon JO and Copple BL: Upregulation of early growth response factor-1 by bile acids requires mitogen-activated protein kinase signaling. Toxicol Appl Pharmacol. 243:63–67. 2010. View Article : Google Scholar : PubMed/NCBI
41	Reiners JJ Jr, Lee JY, Clift RE, Dudley DT and Myrand SP: PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase. Mol Pharmacol. 53:438–445. 1998.PubMed/NCBI
42	Perdew GH: Association of the Ah receptor with the 90-kDa heat shock protein. J Biol Chem. 263:13802–13805. 1988.PubMed/NCBI
43	Meyer BK and Perdew GH: Characterization of the AhR-hsp90-XAP2 core complex and the role of the immunophilin-related protein XAP2 in AhR stabilization. Biochemistry. 38:8907–8917. 1999. View Article : Google Scholar : PubMed/NCBI
44	Heid SE, Pollenz RS and Swanson HI: Role of heat shock protein 90 dissociation in mediating agonist-induced activation of the aryl hydrocarbon receptor. Mol Pharmacol. 57:82–92. 2000.PubMed/NCBI
45	Refat NA, Ibrahim ZS, Moustafa GG, Sakamoto KQ, Ishizuka M and Fujita S: The induction of cytochrome P450 1A1 by sudan dyes. J Biochem Mol Toxicol. 22:77–84. 2008. View Article : Google Scholar : PubMed/NCBI
46	Lubet RA, Connolly G, Kouri RE, Nebert DW and Bigelow SW: Biological effects of the Sudan dyes. Role of the Ah cytosolic receptor. Biochem Pharmacol. 32:3053–3058. 1983. View Article : Google Scholar : PubMed/NCBI
47	Dewa Y, Nishimura J, Muguruma M, Jin M, Kawai M, Saegusa Y, Okamura T, Umemura T and Mitsumori K: Involvement of oxidative stress in hepatocellular tumor-promoting activity of oxfendazole in rats. Arch Toxicol. 83:503–511. 2009. View Article : Google Scholar : PubMed/NCBI